TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania
-
Essen, Alemania
-
Frankfurt, Alemania
-
Hamburg, Alemania
-
Hannover, Alemania
-
Köln, Alemania
-
Mannheim, Alemania
-
-
-
-
-
Darlinghurst, Australia
-
Prahran, Australia
-
Surry Hills, Australia
-
-
-
-
-
Campinas, Brasil
-
Distrito Barao Geraldo-Campina, Brasil
-
Pinheiros, Brasil
-
Recife, Brasil
-
Sao Paulo, Brasil
-
-
-
-
-
Antwerpen, Bélgica
-
Brussels, Bélgica
-
Gent, Bélgica
-
Leuven, Bélgica
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá
-
-
British Columbia
-
Vancouver, British Columbia, Canadá
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá
-
-
Ontario
-
Toronto, Ontario, Canadá
-
-
Quebec
-
Montreal, Quebec, Canadá
-
-
-
-
-
Providencia, Chile
-
Santiago, Chile
-
-
-
-
-
San Jose, Costa Rica
-
-
-
-
-
Barcelona, España
-
Barcelona N/A, España
-
Elche, España
-
Madrid, España
-
-
-
-
California
-
Long Beach, California, Estados Unidos
-
Los Angeles, California, Estados Unidos
-
San Francisco, California, Estados Unidos
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos
-
-
Florida
-
Atlantis, Florida, Estados Unidos
-
Miami, Florida, Estados Unidos
-
Miami Beach, Florida, Estados Unidos
-
Orlando, Florida, Estados Unidos
-
Tampa, Florida, Estados Unidos
-
-
Illinois
-
Chicago, Illinois, Estados Unidos
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos
-
Springfield, Massachusetts, Estados Unidos
-
-
Michigan
-
Detroit, Michigan, Estados Unidos
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos
-
-
New Jersey
-
Newark, New Jersey, Estados Unidos
-
-
New York
-
Bronx, New York, Estados Unidos
-
Flushing, New York, Estados Unidos
-
New York, New York, Estados Unidos
-
Rochester, New York, Estados Unidos
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos
-
-
Texas
-
Dallas, Texas, Estados Unidos
-
Houston, Texas, Estados Unidos
-
Longview, Texas, Estados Unidos
-
-
-
-
-
Moscow N/A, Federación Rusa
-
Saint-Petersburg, Federación Rusa
-
Smolensk, Federación Rusa
-
Voronezh, Federación Rusa
-
-
-
-
-
Clamart, Francia
-
Le Kremlin Bicetre, Francia
-
Montpellier, Francia
-
Paris, Francia
-
-
-
-
-
Chennai, India
-
Nagpur, India
-
-
-
-
-
Guadalajara N/A, México
-
Mexico City, México
-
-
-
-
-
Panama, Panamá
-
Panama City N/A, Panamá
-
-
-
-
-
Beijing, Porcelana
-
Guangzhou, Porcelana
-
Shanghai, Porcelana
-
-
-
-
-
Porto, Portugal
-
-
-
-
-
San Juan, Puerto Rico
-
-
-
-
-
London, Reino Unido
-
Manchester, Reino Unido
-
-
-
-
-
Bloemfontein, Sudáfrica
-
Cape Town, Sudáfrica
-
Dundee, Sudáfrica
-
Johannesburg, Sudáfrica
-
Pretoria N/A, Sudáfrica
-
Westdene Johannesburg Gauteng, Sudáfrica
-
-
-
-
-
Bangkok, Tailandia
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient with documented HIV-1 infection
- Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening
- Patient's HIV-1 plasma viral load at screening is > 5,000 HIV-1 RNA copies/mL (assayed by RNA PCR standard specimen procedure)
- Patient's virus is sensitive to the 2 nucleoside/nucleotide reverse transcriptase inhibitors chosen for treatment
- Patient agrees not to start ART before the baseline visit
- Patient is HLA-B*5701 negative in case abacavir is included in the patient's treatment regimen.
Exclusion Criteria:
- Previous use of ANY ARV drug for ANY length of time
- Any documented evidence of NNRTI resistance associated mutations in patient's HIV
- Category C AIDS defining illness, except, Stable Kaposi Sarcoma Wasting syndrome if not progressive
- Pneumocystis carinii pneumonia (PCP) that is considered not cured
- Active TB
- Allergy or hypersensitivity to study or background ARTs
- Specific grade 3 or 4 toxicity
- Kidney impairment: calculated creatinine clearance <50 ml/min
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: 002
efavirenz 600 mg tablet once daily for 96 weeks
|
600 mg tablet once daily for 96 weeks
|
|
Experimental: 001
TMC278 25 mg tablet once daily for 96 weeks
|
Comprimido de 25 mg una vez al día durante 96 semanas
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48
Periodo de tiempo: Week 48
|
Virological response is defined as confirmed plasma viral load less than (<) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48.
The TLOVR algorithm was used to derive response.
Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation.
Resuppression after confirmed virologic failure was considered as failure.
Virologic Failure includes participants who were rebounder (confirmed viral load >= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load <50 copies/ml).
|
Week 48
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cambio medio desde el inicio hasta la semana 48 y la semana 96 en los recuentos absolutos y relativos de células CD4+ (usando datos imputados)
Periodo de tiempo: Línea de base, semana 48 y semana 96
|
Se imputó el cambio desde el valor inicial en el recuento de células CD4+ en caso de que faltaran valores: en caso de interrupción prematura, los datos se imputaron con el valor inicial después de la interrupción (es decir,
change=0, Non-Complete [NC] = Fallo); de lo contrario, se aplicó la última observación llevada adelante.
|
Línea de base, semana 48 y semana 96
|
|
Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 48
Periodo de tiempo: Week 48
|
The analysis is based on the last observed viral load (VL) data within the Week 48 window.
Virologic response is defined as a VL<50 copies/mL (observed case).
Missing VL was considered as non-response.
Virologic Failure includes subjects who had VL>=50 copies/mL in the Wk 48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL>=50 copies/mL and subjects who had a switch in background regimen that was not permitted by the protocol.
|
Week 48
|
|
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 96
Periodo de tiempo: Week 96
|
Week 96
|
|
|
Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 96
Periodo de tiempo: Week 96
|
Week 96
|
|
|
Number of Participants With Virological Response (Observed, <50 Copies/mL) at Last On-Treatment Visit (Post-Week 96).
Periodo de tiempo: Variable, ranging from 3 months up to maximum 18 months for TMC278 and 12 months for Efavirenz
|
Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per mL at the last on-treatment post-Week 96 visit.
|
Variable, ranging from 3 months up to maximum 18 months for TMC278 and 12 months for Efavirenz
|
|
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 48
Periodo de tiempo: Week 48
|
Virological response is defined as confirmed plasma viral load < 400 HIV-1 (RNA) copies/mL at Week 48.
The TLOVR algorithm was used to derive response.
Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation.
Resuppression after confirmed virologic failure was considered as failure.
Virologic Failure includes participants who were rebounder (confirmed viral load >= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load <400 copies/mL).
|
Week 48
|
|
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 96
Periodo de tiempo: Week 96
|
Virological response is defined as confirmed plasma viral load < 400 HIV-1 (RNA) copies/mL at Week 96.
The TLOVR algorithm was used to derive response.
Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation.
Resuppression after confirmed virologic failure was considered as failure.
Virologic Failure includes participants who were rebounder (confirmed viral load >= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load <400 copies/mL).
|
Week 96
|
|
Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure
Periodo de tiempo: Week 96
|
Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load <50 copies/mL) and plasma viral load increase of >=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load >=50 copies/mL after having had 2 consecutive plasma viral load <50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load >=50 copies/mL after having had 2 consecutive plasma viral load <50 copies/mL.
For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).
|
Week 96
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Rimsky L, Van Eygen V, Hoogstoel A, Stevens M, Boven K, Picchio G, Vingerhoets J. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir Ther. 2013;18(8):967-77. doi: 10.3851/IMP2636. Epub 2013 May 28.
- Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, Li T, Tebas P, Stevens M, Buelens A, Vanveggel S, Boven K; ECHO and THRIVE Study Groups. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother. 2012 Aug;67(8):2020-8. doi: 10.1093/jac/dks130. Epub 2012 Apr 24.
- Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229-37. doi: 10.1016/S0140-6736(11)60983-5.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de la transcriptasa inversa
- Inhibidores de la síntesis de ácidos nucleicos
- Inhibidores de enzimas
- Agentes Anti-VIH
- Agentes antirretrovirales
- Inhibidores de enzimas del citocromo P-450
- Inductores de enzimas de citocromo P-450
- Inductores de citocromo P-450 CYP3A
- Inductores de citocromo P-450 CYP2B6
- Inhibidores del citocromo P-450 CYP2C9
- Inhibidores del citocromo P-450 CYP2C19
- Efavirenz
- Rilpivirina
Otros números de identificación del estudio
Otros números de identificación del estudio
- CR002704
- TMC278-TIDP6-C215 (Otro identificador: Tibotec Pharmaceuticals, Ireland)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .